Chronic Myelogenous Leukemia

Thrombopoietin and Its Receptor Not Involved In Disease Progression

Published in Blood Weekly, March 16th, 2000

Neither thrombopoietin (TPO) nor its receptor, c-mpl, play a significant role in the progression of chronic myelogenous leukemia (CML), according to researchers.

Because TPO and c-mpl support the proliferation of multiple types of immature hematopoietic progenitor cells and induce clonal growth of leukemic cells, K. Kaban and colleagues investigated whether overexpression of (TPO) or c-mpl might correlate with progression of CML, disease aggressiveness, or response to therapy ("Expression of thrombopoietin and its receptor (C-mpl) in chronic myelogenous leukemia - Correlation with disease progression and response to therapy," Cancer, 2000;88(3):570-576).

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2000-03-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry